RE:G12C/G12V KRAS mutation in PC & CRC patients respond to Pela Should read:
G12D/G12V KRAS mutation in PC & CRC patients respond to Pelareorep
The KRAS protein normally acts like an on–off switch. In response to certain signals, it becomes activated and tells the cell to grow and divide. When the signals are no longer present, it turns off. However, some mutant forms of KRAS, such as KRAS G12D, remain active even in the absence of growth signals, leading to uncontrolled cell growth.
The KRAS G12D mutation is present in more than one in three pancreatic cancers, about one in ten colorectal cancers, and in several other cancer types.
ONCYs pelareorep is able turn off KRAS G12D and in so doing reverse the immunospressive tumor microenvironment (TME) in advance of the addition of immune checkpoint inhibition such as atezolizumab.